To compare the efficacy and safety of remimazolam combined with propofol and sufentanil in fiberoptic bronchoscopy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040626

Enrollment

Unknown

Registered

2020-12-04

Start date

2020-11-19

Completion date

Unknown

Last updated

2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia for microsurgery

Interventions

group p:propofol

group L:low remimazolam

group H:high remimazolam

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled to undergo painless fiberoptic bronchoscopy; 2. aged from 18 to 65 years; 3. ASA grade I ~ II, preoperative no serious cardiopulmonary disease, normal liver and kidney function, no mental disease; 4. Body mass index (BMI) 18 ~ 28kg /m2.

Exclusion criteria

Exclusion criteria: 1. Unaccompanied or unaccompanied; 2. Uncontrolled severe hypertension, severe arrhythmia, and unstable angina; 3. Liver dysfunction (Child-Pugh grade C or above); 4. Severe renal dysfunction (Cr clearance rate < 30 ml /min); 5, Allergic to drugs or have allergies to drugs or other contraindications.

Design outcomes

Primary

Measure	Time frame
blood pressure;degree of blood oxygen saturation;heart rate;adverse reaction;	—

Countries

China

Contacts

Public ContactRui Xue

People Hospital Of Shiyan City

xuerui1106@126.com+86 13476167178

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026